JO
AGRX

John Overdeck’s Agile Therapeutics AGRX Stock Holding History

John Overdeck’s Portfolio AGRX Stock Details AGRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-201
Closed -$2.25K – 3441
2023
Q1 		$2.25K Sell
201
-6
-3% -$77 ﹤0.01% 2917
2022
Q4 		$2.35K Sell
207
-352
-63% -$4.09K ﹤0.01% 2764
2022
Q3 		$8K Sell
559
-349
-38% -$8.59K ﹤0.01% 2421
2022
Q2 		$53K Buy
+908
New +$132K ﹤0.01% 2340
2021
Q3 		– Sell
-7
Closed -$19K – 4882
2021
Q2 		$19K Buy
+7
New +$23.1K ﹤0.01% 3957
2021
Q1 		– Sell
-175
Closed -$1M – 4359
2020
Q4 		$1M Buy
175
+86
+97% +$506K ﹤0.01% 2007
2020
Q3 		$541K Sell
89
-7
-7% -$40.1K ﹤0.01% 2186
2020
Q2 		$532K Buy
96
+19
+25% +$98.7K ﹤0.01% 1960
2020
Q1 		$288K Buy
77
+17
+28% +$97.6K ﹤0.01% 2343
2019
Q4 		$298K Buy
+60
New +$210K ﹤0.01% 3194
2018
Q4 		– Sell
-30
Closed -$22K – 3663
2018
Q3 		$22K Buy
30
+15
+100% +$11K ﹤0.01% 3113
2018
Q2 		$15K Buy
+15
New +$52.6K ﹤0.01% 3242

Other funds holding AGRX

AC
Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
TRCT
Tower Research Capital (TRC) New York $4.08B AUM 58.77% 1-Year Est. Return
IA
Investor AB Stockholm, Sweden $14.4B AUM 4.07% 1-Year Est. Return
Royal Bank of Canada
Royal Bank of Canada Toronto, Ontario, Canada $672B AUM 33.48% 1-Year Est. Return
Citigroup
Citigroup New York $303B AUM 53.02% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
Osaic Holdings
Osaic Holdings Scottsdale, Arizona $85.1B AUM 27.35% 1-Year Est. Return

John Overdeck's AGRX Position: Q2 2023 in Review

John Overdeck sold out of Agile Therapeutics (AGRX) in Q2 2023, closing a stake of 201 shares — an estimated $2.25K sold.

John Overdeck first reported a position in AGRX in Q2 2018 and held it in 12 quarters. The position peaked at $1M in Q4 2020. 16 funds tracked by Wall St. Rank hold AGRX as of Q2 2023.

  • John Overdeck reported no remaining Agile Therapeutics position as of Q2 2023 after selling out during the quarter.
  • John Overdeck sold 201 Agile Therapeutics shares in Q2 2023, an estimated $2.25K.
  • John Overdeck first reported a position in Agile Therapeutics in Q2 2018 and held it in 12 quarters.
  • John Overdeck's Agile Therapeutics position peaked at $1M in Q4 2020.
  • 16 funds tracked by Wall St. Rank held Agile Therapeutics as of Q2 2023.

Based on Two Sigma Investments's 13F filing for Q2 2023, filed 14 Aug 2023.